cyclophosphamide + epirubicin + exemestane + nivolumab

This is a multi-agent combination regimen consisting of four drugs with distinct mechanisms of action, primarily investigated or considered for the treatment of breast cancer. - **Cyclophosphamide** is an alkylating agent that crosslinks DNA, leading to cell death in rapidly dividing cells. - **Epirubicin** is an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, resulting in inhibition of DNA replication and repair. - **Exemestane** is a steroidal aromatase inhibitor that irreversibly blocks estrogen synthesis by inhibiting the aromatase enzyme, reducing estrogen-driven tumor growth in hormone receptor-positive breast cancer. - **Nivolumab** is a monoclonal antibody targeting programmed cell death protein 1 (PD-1), acting as an immune checkpoint inhibitor to enhance T-cell mediated anti-tumor responses. This specific four-drug combination does not have a unique brand name or established clinical protocol but represents an investigational approach combining cytotoxic chemotherapy (cyclophosphamide, epirubicin), endocrine therapy (exemestane), and immunotherapy (nivolumab). Each component has been individually approved for various cancers; combinations including subsets of these agents are standard in breast cancer management[1][2][3][4][5][6][7]. Nivolumab adds immunotherapeutic potential to traditional regimens.

Other names

cyclophosphamide and epirubicin and exemestane and nivolumabcyclophosphamide/epirubicin/exemestane/nivolumab